6978 — Immunotech Biopharm Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.65bn
- HK$1.59bn
Annual cashflow statement for Immunotech Biopharm, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -109 | -439 | -355 | -321 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -0.665 | 191 | 59.9 | 37.5 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.31 | -29.3 | 19.1 | 58.6 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -95.5 | -264 | -255 | -181 | — |
| Capital Expenditures | -21 | -75.7 | -181 | -96.6 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 46.8 | -128 | -147 | 120 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 25.7 | -204 | -328 | 23.4 | — |
| Financing Cash Flow Items | 44.2 | -77.9 | -3.68 | -6.13 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 217 | 1,055 | -11 | -36.1 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 154 | 563 | -594 | -193 | — |